3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
11
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Sarcoma
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Interventions
Cisplatin
27
Cetuximab
17
Radiotherapy
14
Carboplatin
14
pembrolizumab
11
Paclitaxel
11
Drug Therapy
8
Radiotherapy, Intensity-Modulated
7
Nivolumab
7
Fluorouracil
7
Erlotinib Hydrochloride
7
Radiation
6
Docetaxel
5
130-nm albumin-bound paclitaxel
5
Panitumumab
4
Chemoradiotherapy
3
Capecitabine
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Afatinib
3
selinexor
2
figitumumab
2
Restraint, Physical
2
Radiosurgery
2
Methotrexate
2
Lapatinib
2
Everolimus
2
Esophagectomy
2
Cyclophosphamide
2
zalutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Squamous Cell
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts